Cancer Therapeutics (CT) Program

The goal of the Cancer Therapeutics (CT) Program is to foster the development of novel therapeutic, chemopreventive and biomarker strategies that can be translated into more effective clinical applications through proof-of-principle, early-phase clinical and correlative science studies.

The thematic areas and specific aims of the CT Program are:

1. Drug Development and Delivery: To foster the development and enhanced delivery of new therapeutic and preventive agents.
2. Biomarkers: To promote discovery and utilization of biomarkers that can be used for diagnosis, prognosis and prediction of response.
3. Developmental Therapeutics: To design and conduct innovative early-phase clinical trials integrated with correlative science studies.

• Lacey McNally, PhD Program Co-Leader
• Kathleen Moore, MD Program Co-Leader (Interim)

VIEW PROGRAM MEMBERS